|
EU must bolster biosimilar medicines policy to increase equity of access and bring much needed savings to healthcare budgets |
Medicines for Europe |
25 May 2023 |
Health & Consumers |
|
Medicines for Europe joins the Antimicrobial (AMR) One Health Network |
Medicines for Europe |
09 May 2023 |
Health & Consumers |
|
Future of pharmaceutical policy rests on secure supply of essential medicines |
Medicines for Europe |
03 May 2023 |
Health & Consumers |
|
Patients should benefit from greater access under new patent package proposals |
Medicines for Europe |
28 Apr 2023 |
Health & Consumers |
|
Reaction to EU Pharmaceutical legislation: Timely and equitable access for patients and security of supply essential for reform |
Medicines for Europe |
27 Apr 2023 |
Health & Consumers |
|
Harmonised bioequivalence guideline paves the way for global generic medicine development and access to medicines |
Medicines for Europe |
26 Apr 2023 |
Health & Consumers |
|
Market reforms needed to secure essential antibiotics against AMR, report says |
Medicines for Europe |
16 Feb 2023 |
Health & Consumers |
|
EU can do more for equitable access to medicines |
Medicines for Europe |
13 Jan 2023 |
Health & Consumers |
|
Billions more euros to re-invest in better healthcare thanks to biosimilar medicines |
Medicines for Europe |
14 Dec 2022 |
Health & Consumers |
|
2022 Health at a Glance Report highlights the need to rethink investments in health after the COVID-19 pandemic |
Medicines for Europe |
05 Dec 2022 |
Health & Consumers |
|
Giving medicines a new life: EU should foster patients’ access to Value Added Medicines |
Medicines for Europe |
30 Nov 2022 |
Health & Consumers |
|
Pharmaceutical legislation reforms must support equitable access to medicine in Central and Eastern Europe and security of medicines supplies |
Medicines for Europe |
17 Nov 2022 |
Health & Consumers |
|
Proposals on wastewater treatment will jeopardise patient access to medicines without helping green transition |
Medicines for Europe |
27 Oct 2022 |
Health & Consumers |
|
Energy Council (TTE) – Medicines for Europe Open letter to European Energy Ministers and responsible European Commissioners on inflation and energy costs impacting the supply of essential generic medicines |
Medicines for Europe |
28 Sep 2022 |
Health & Consumers |
|
EMA/HMA share definitive EU-wide position on biosimilar medicines interchangeability |
Medicines for Europe |
20 Sep 2022 |
Health & Consumers |
|
Medicines for Europe warns strongly against energy rationing for medicines production |
Medicines for Europe |
20 Jul 2022 |
Health & Consumers |
|
The off-patent medicines industry is a vital part of the solution for healthcare resilience |
Medicines for Europe |
30 Jun 2022 |
Health & Consumers |
|
Smart reform of EU pharma and IP legislation key to boosting access to essential medicines |
Medicines for Europe |
30 Jun 2022 |
Health & Consumers |
|
EU can do more for patients with smart use of biosimilar medicines |
Medicines for Europe |
29 Apr 2022 |
Health & Consumers |
|
Central & Eastern European patients have inequitable access to medicines for life-threatening conditions |
Medicines for Europe |
25 Apr 2022 |
Health & Consumers |
|
Repurposing: a golden opportunity for patient centric health investment in Europe |
Medicines for Europe |
06 Apr 2022 |
Health & Consumers |
|
Electronic product information: new report shows it is time to move from principles to action |
Medicines for Europe |
25 Feb 2022 |
Health & Consumers |
|
The European Commission needs to prioritise equitable access to biosimilar medicines in Europe |
Medicines for Europe |
25 Jan 2022 |
Health & Consumers |
|
Regulatory reforms critical to improve patient access to medicines |
Medicines for Europe |
24 Jan 2022 |
Health & Consumers |
|
Stronger mandate for European Medicines Agency should prioritise patient access to medicines |
Medicines for Europe |
24 Jan 2022 |
Health & Consumers |
|
Biosimilar medicines have delivered 18BN€ total savings for Europe but more action needed to translate this potential into patient access and sustainable health systems |
Medicines for Europe |
16 Dec 2021 |
Health & Consumers |
|
Commission study highlights market framework conditions are main driver for medicines shortages |
Medicines for Europe |
10 Dec 2021 |
Health & Consumers |
|
Access to essential medicines threatened by combination of increasing inflation and potential further price cuts in EU countries |
Medicines for Europe |
26 Nov 2021 |
Health & Consumers |
|
European Parliament report calls for increased use of off-patent medicines to improve patient access |
Medicines for Europe |
25 Nov 2021 |
Health & Consumers |
|
The EU must stop the offshoring of essential medicines manufacturing investments: ambitious, open and coherent policies must support competitive, robust and sustainable production of APIs and medicines |
Medicines for Europe |
23 Nov 2021 |
Global Europe |
